Gentian Diagnostics AS Total Liabilities
Gentian Diagnostics AS total liabilities. Based on the latest financial reports, Gentian Diagnostics AS (GENT) has total liabilities worth Nkr53.58 Million NOK (≈ $5.64 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Gentian Diagnostics AS defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Gentian Diagnostics AS (2013–2025)
Total liabilities of Gentian Diagnostics AS from 2013 to 2025. This chart illustrates how Gentian Diagnostics AS's total liabilities have evolved over time, based on quarterly financial data. Check GENT financial resilience to evaluate the company's liquid asset resilience ratio.
Gentian Diagnostics AS Competitors by Total Liabilities
The table below lists competitors of Gentian Diagnostics AS ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Media Prima Bhd
KLSE:4502
|
Malaysia | RM635.68 Million |
|
United Radiant Technology
TWO:5315
|
Taiwan | NT$534.46 Million |
|
Ilyda SA
AT:ILYDA
|
Greece | €5.47 Million |
|
ALM EQUITY AB
F:I53
|
Germany | €1.86 Billion |
|
Sumber Energi Andalan Tbk PT
JK:ITMA
|
Indonesia | Rp42.57 Million |
|
Laboratorios Richmond SACIF
BA:RICH
|
Argentina | AR$282.24 Billion |
|
Lytix Biopharma AS
OL:LYTIX
|
Norway | Nkr19.77 Million |
|
Professional Computer Technology Ltd
TWO:6270
|
Taiwan | NT$1.19 Billion |
Liability Composition Analysis (2013–2025)
This chart breaks down Gentian Diagnostics AS's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of Gentian Diagnostics AS.
Liquidity & Leverage Metrics
Gentian Diagnostics AS Total Liabilities Ratios Explained
Gentian Diagnostics AS total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.40 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 3.10 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.26 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.21 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Gentian Diagnostics AS's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Gentian Diagnostics AS (2013–2025)
The table below shows the annual total liabilities of Gentian Diagnostics AS from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Nkr53.58 Million ≈ $5.64 Million |
+50.45% |
| 2024-12-31 | Nkr35.61 Million ≈ $3.75 Million |
+3.52% |
| 2023-12-31 | Nkr34.40 Million ≈ $3.62 Million |
+2.33% |
| 2022-12-31 | Nkr33.62 Million ≈ $3.54 Million |
-9.19% |
| 2021-12-31 | Nkr37.02 Million ≈ $3.90 Million |
-9.00% |
| 2020-12-31 | Nkr40.69 Million ≈ $4.28 Million |
+114.78% |
| 2019-12-31 | Nkr18.94 Million ≈ $1.99 Million |
+56.47% |
| 2018-12-31 | Nkr12.11 Million ≈ $1.27 Million |
+38.29% |
| 2017-12-31 | Nkr8.75 Million ≈ $921.24K |
+18.00% |
| 2016-12-31 | Nkr7.42 Million ≈ $780.68K |
+51.53% |
| 2015-12-31 | Nkr4.90 Million ≈ $515.21K |
-58.78% |
| 2014-12-31 | Nkr11.88 Million ≈ $1.25 Million |
-5.36% |
| 2013-12-31 | Nkr12.55 Million ≈ $1.32 Million |
-- |
About Gentian Diagnostics AS
Gentian Diagnostics ASA develops, manufactures, and sells biochemical reagents for use in medical diagnostics and research in the United States, Asia, and Europe. The company offers in-vitro diagnostic reagents for clinical chemistry analyzers, such as Gentian Circulating Calprotectin Immunoassay, a turbidimetric assay used for the measurement of calprotectin in plasma and serum for detection and… Read more